Direct-acting Antiviral Therapy for Mixed Genotype Chronic Hepatitis C Infection
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 2
Abstract
Objectives: Literature data concerning the outcomes of direct acting antiviral (DAA) therapy in mixed genotype hepatitis C virus (HCV) infections are very limited, and the incidence of mixed HCV infection in Turkey is unknown. The aim of this study was to investigate the prevalence of mixed genotype chronic HCV infection, risk factors related to mode of transmission and outcomes of DAA therapy in these patients. Materials and Methods: Patients with two different HCV genotypes identified in the same blood sample during a 20-month period were analyzed retrospectively in terms of treatment received, adherence and response to treatment and risk factors related to mode of transmission. Results: During the study period, mix genotypes were detected in 21 (4.2%) out of 495 patients with chronic HCV infection. Fifteen patients (71%) had a history of intravenous drug use. Eleven patients who received DAA treatment was HCV-RNA negative at the end of treatment. Conclusion: According to our findings, infection with different HCV genotypes is possible in patients with repeated HCV exposure, such as intravenous drug users, but mixed HCV infection can be successfully treated with DAA therapy. In addition, our study may be noteworthy for also including mixed genotypes in the HCV epidemiological shift in our region.
Authors and Affiliations
Bedia Mutay Suntur, Nevzat Ünal, Hava Kaya, Banu Kara, Halime Betül Şahin Eker
Keywords
Related Articles
- EP ID EP633773
- DOI 10.4274/vhd.galenos.2019.2019.0013
- Views 83
- Downloads 0
An Important Financial Burden: Unnecessary Test Requests for Viral Hepatitis
Editorial
The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy
Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, pat...
Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
Objectives: It was aimed to evaluate health-related quality of life of patients with non-cirrhotic chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during interferon therapy with the standard short form-36 (SF-36)...
Frequency of Hepatitis B Virus, Hepatitis C Virus and HIV Infections in Cannabis and Opioid Addicts
Objective: There are very few data about the epidemiology of hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV infections in drug addicts in Turkey, whereas several countries have a developed surveillance systems...
Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping
Current direct-acting antivirals (DAAs) have high success rates in the treatment of chronic hepatitis C virus (HCV) infection. However, 1-15% of patients fail to achieve viral eradication. Some factors may play a role in...